From GlobeNewswire: 2025-02-12 07:42:23

Ocugen, Inc. has completed Phase 2 enrollment for their OCU410 gene therapy trial for geographic atrophy (GA) in age-related macular degeneration (AMD). The Phase 1/2 study showed positive safety and tolerability results, with no serious adverse events related to OCU410. Patients treated with OCU410 demonstrated slower lesion growth and improved visual function compared to untreated eyes. The trial aims to offer a one-time treatment option for GA, a later stage of dAMD. With enrollment complete, the Phase 2 study will assess the safety and efficacy of OCU410 in patients with GA. In a Phase 1/2 study, OCU410 demonstrated a positive safety profile with no serious adverse events related to the treatment, including no cases of specific eye conditions. Phase 2 enrollment has been completed with 51 subjects randomized into treatment and control arms. The study showed favorable safety and tolerability, paving the way for further development and potential regulatory filings. For more information, visit the Ocugen website and follow their updates on LinkedIn. Contact Tiffany Hamilton, AVP and Head of Communications, for further inquiries at [email protected]. The Phase 2 enrollment for OCU410 has been completed, with 51 subjects randomized into treatment and control arms. The Phase 1/2 study involving 60 participants showed a favorable safety and tolerability profile for OCU410, with no serious adverse events related to the drug. There were no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis, or choroidal neovascularization reported during the study.



Read more at GlobeNewswire: Ocugen, Inc. Announces Dosing Completion in the Phase 2